1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 39, 26/Sep/2024
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

Influenza viruses can cause large seasonal epidemics with high healthcare impact and severity as they continually change their virological properties such as genetic makeup over time.

Aim

We aimed to monitor the characteristics of circulating influenza viruses over the 2022/23 influenza season in the EU/EEA countries. In addition, we wanted to compare how closely the circulating viruses resemble the viral components selected for seasonal influenza vaccines, and whether the circulating viruses had acquired resistance to commonly used antiviral drugs.

Methods

We performed a descriptive analysis of the influenza virus detections and characterisations reported by National Influenza Centres (NIC) from the 30 EU/EEA countries from week 40/2022 to week 39/2023 to The European Surveillance System (TESSy) as part of the Global Influenza Surveillance and Response System (GISRS).

Results

In the EU/EEA countries, the 2022/23 influenza season was characterised by co-circulation of A(H1N1)pdm09, A(H3N2) and B/Victoria-lineage viruses. The genetic evolution of these viruses continued and clade 6B.1A.5a.2a of A(H1N1)pdm09, 3C.2a1b.2a.2b of A(H3N2) and V1A.3a.2 of B/Victoria viruses dominated. Influenza B/Yamagata-lineage viruses were not reported.

Discussion

The World Health Organization (WHO) vaccine composition recommendation for the northern hemisphere 2023/24 season reflects the European virus evolution, with a change of the A(H1N1)pdm09 component, while keeping the A(H3N2) and B/Victoria-lineage components unchanged.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.39.2400020
2024-09-26
2024-09-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.39.2400020
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/39/eurosurv-29-39-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.39.2400020&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 24 Nov 2023]. Available from: https://erviss.org
  2. European Centre for Disease Prevention and Control. Reporting Protocol for integrated respiratory virus surveillance, version 1.3. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/reporting-protocol-integrated-respiratory-virus-surveillance-version-13
  3. Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci AJ, et al. Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021;26(11):2100221.  https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100221  PMID: 33739256 
  4. Adlhoch C, Mook P, Lamb F, Ferland L, Melidou A, Amato-Gauci AJ, et al. Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021;26(11):2100221.  https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100221  PMID: 33739256 
  5. Melidou A, Hungnes O, Pereyaslov D, Adlhoch C, Segaloff H, Robesyn E, et al. Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019. Vaccine. 2020;38(35):5707-17.  https://doi.org/10.1016/j.vaccine.2020.06.031  PMID: 32624252 
  6. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall. 2017;1(1):33-46.  https://doi.org/10.1002/gch2.1018  PMID: 31565258 
  7. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season
  8. Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation calling and quality control for viral genomes. J Open Source Softw. 2021;6(67):3773.  https://doi.org/10.21105/joss.03773 
  9. European Centre for Disease Prevention and Control (ECDC) and World Health Organization Regional Office of Europe (WHO/Europe). Joint WHO/ECDC influenza virus characterisation report, summary of TESSy virus characterisation data 2017/18. Stockholm: ECDC and WHO/EURO; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-report-summary-17-18
  10. World Health Organization (WHO). Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)
  11. World Health Organization (WHO). Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavir-susceptibility
  12. Melidou A, Ködmön C, Nahapetyan K, Kraus A, Alm E, Adlhoch C, et al. Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22. Euro Surveill. 2022;27(15):2200255.  https://doi.org/10.2807/1560-7917.ES.2022.27.15.2200255  PMID: 35426364 
  13. European Centre for Disease Prevention and Control WHO. FluNewsEurope, Joint ECDC-WHO/Europe weekly influenza update - Archive. Stockholm: ECDC, WHO/Europe. [Accessed: 12 Oct 2023]. Available from: https://www.ecdc.europa.eu/en/publications-data/flu-news-europe-bulletins-season-2022-2023
  14. Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28(21):2300116.  https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116  PMID: 37227299 
  15. McLean HQ, Petrie JG, Hanson KE, Meece JK, Rolfes MA, Sylvester GC, et al. Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(8):201-5.  https://doi.org/10.15585/mmwr.mm7208a1  PMID: 36821715 
  16. Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, et al. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23. Euro Surveill. 2023;28(5):2300043.  https://doi.org/10.2807/1560-7917.ES.2023.28.5.2300043  PMID: 36729117 
  17. Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat Rev Microbiol. 2021;19(12):741-2.  https://doi.org/10.1038/s41579-021-00642-4  PMID: 34584246 
  18. Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022;27(39):2200753.  https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753  PMID: 36177871 
  19. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season
  20. Bhat YR. Influenza B infections in children: A review. World J Clin Pediatr. 2020;9(3):44-52.  https://doi.org/10.5409/wjcp.v9.i3.44  PMID: 33442534 
  21. Johnson FB. Transport of viral specimens. Clin Microbiol Rev. 1990;3(2):120-31.  https://doi.org/10.1128/CMR.3.2.120  PMID: 2187591 
  22. European Centre for Disease Prevention and Control and World Health Organization European Region. Operational considerations for respiratory virus surveillance in Europe. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/operational-considerations-respiratory-virus-surveillance-europe
  23. World Health Organization (WHO). Terms of Reference for National Influenza Centers of the Global Influenza Surveillance and Response System. Geneva: WHO; 2017. Available from: https://cdn.who.int/media/docs/default-source/influenza/national-influenza-centers-files/nic_tor_en.pdf?sfvrsn=93513e78_30
Co-circulation of seasonal influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage viruses with further genetic diversification, EU/EEA, 2022/23 influenza season
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Eeva+K+Broberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Broberg Eeva K</a>, <a href="/search?value1=Olov+Svartstr%C3%B6m&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Svartström Olov</a>, <a href="/search?value1=Maximilian+Riess&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riess Maximilian</a>, <a href="/search?value1=Annette+Kraus&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kraus Annette</a>, <a href="/search?value1=Maja+Vukovikj&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vukovikj Maja</a>, <a href="/search?value1=Angeliki+Melidou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Melidou Angeliki</a>, <a href="/search?value1=Members+of+the+European+Reference+Laboratory+Network+for+Human+Influenza+%28ERLI-Net%29&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Members of the European Reference Laboratory Network for Human Influenza (ERLI-Net)</a></span>. Co-circulation of seasonal influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage viruses with further genetic diversification, EU/EEA, 2022/23 influenza season. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(39):pii=2400020. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.39.2400020" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.39.2400020</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 03 Jan 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 17 Jun 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.39.2400020
/content/10.2807/1560-7917.ES.2024.29.39.2400020
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error